Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Tuesday, September 25, 2018 · 463,012,095 Articles · 3+ Million Readers

Neurofibromatoses Type I Trends, Analysis and Review during H1 2017 To 2022

Healthcare

Healthcare

PUNE, MAHARASHTRA, INDIA, April 12, 2018 /EINPresswire.com/ -- Neurofibromatoses Type I

Summary 

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Click here for sample report @ http://www.wiseguyreports.com/sample-request/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017

Report Highlights

The  Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

 Table of Contents 

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development
Alexion Pharmaceuticals Inc
Array BioPharma Inc  .Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1510560-neurofibromatoses-type-i-von-recklinghausen-s-disease-pipeline-review-h1-2017

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire